Anthony Fauci, MD, announced Monday he is stepping down in December 2022 from his various positions, including as head of the National Institute of Allergy and Infectious Diseases, “to pursue the next chapter of my career” and that he is not retiring.
Anthony Fauci, MD, announced Monday he is stepping down in December 2022 from the positions of director of the National Institute of Allergy and Infectious Diseases (NIAID), chief of the NIAID Laboratory of Immunoregulation, and chief medical advisor to the president.
Fauci, 81, said in a statement released by the National Institutes of Health that he is leaving “to pursue the next chapter of my career” and that he is not retiring.
“I want to use what I have learned as NIAID Director to continue to advance science and public health and to inspire and mentor the next generation of scientific leaders as they help prepare the world to face future infectious disease threats.”
Fauci began leading the NIAID 38 years ago under President Ronald Reagan. After Reagan, he served 6 more presidents, Republicans and Democrats alike, and oversaw reponses to HIV/AIDS, the West Nile virus, anthrax attacks, Ebola and Zika viruses, and the COVID-19 pandemic.
He was awarded the Presidential Medal of Freedom in 2008 by President George W. Bush.
In a statement, President Joe Biden praised Fauci’s long public service career, saying that as vice president, “I came to know him as a dedicated public servant, and a steady hand with wisdom and insight honed over decades at the forefront of some of our most dangerous and challenging public health crises.”
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
Navigating Medicare's Part D Subsidy Program to Achieve Value-Based Care
May 26th 2023On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.
Listen
Health Equity Conversations: Managing Underserved Communities and Value-Based Payment
May 23rd 2023On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.
Listen
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
March 19th 2024The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment pf Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Read More
6 Blood Biomarkers Identified to Predict CVD Risk in Patients With Rheumatoid Arthritis
March 15th 2024Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.
Read More